Overview
OncoCyte Corporation, based in the United States, operates primarily in the biotechnology industry, focusing on the development and commercialization of diagnostic solutions for lung cancer. The company is dedicated to advancing early detection and helping to manage treatment decisions with minimally invasive tests tailored to detect molecular changes and malignancies in patients. A key project includes the commercialization of DetermaRx, a treatment stratification test designed to identify high-risk patients among those who have undergone surgical resection for early-stage lung cancer. Additionally, OncoCyte is developing DetermaIO, a diagnostic test aimed at predicting patient responses to immune checkpoint inhibitor therapies. This innovative line-up places OncoCyte at the forefront of the precision medicine space, addressing critical gaps in cancer diagnosis and treatment.
Basic Stats
The share price of OncoCyte Corporation as of June 17, 2025 is $3.20 / share. The market cap (or net worth) of OncoCyte Corporation as of September 5, 2025 is $91.57 MM.
The Factor Analysis chart (below right) shows a view of OncoCyte Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 91.57 MM |
| EV | 67.29 MM |
| Shares Out. | 28.62 MM |
| Earnings Date | |
| EPS (TTM) | -2.22 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.60 |
| Beta | -0.49 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | -1.44 |
| Price/Book | 83.40 |
| Price/TBV | -6.78 |
| Book/Market | 0.01 |
| EBIT/EV | -0.94 |
| EBIT(3yr avg)/EV | -0.57 |
| ROA | -0.85 |
| ROE | -2.79 |
| ROIC | -14.18 |
| CROIC | 3.36 |
| OCROIC | -5.15 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for OncoCyte Corporation is $5.53. The forecasts range from a low of $4.04 to a high of $8.40. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for OncoCyte Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-01 | Lake Street | Buy | Hold | Downgrade |
| 2022-11-18 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2022-11-14 | Piper Sandler | Overweight | Maintains | |
| 2022-11-11 | Needham | Buy | Maintains | |
| 2022-08-17 | Piper Sandler | Overweight | Maintains | |
| 2022-08-11 | Needham | Buy | Maintains | |
| 2022-08-11 | Lake Street | Buy | Maintains | |
| 2022-05-24 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2022-05-16 | Piper Sandler | Overweight | Maintains | |
| 2022-05-12 | Needham | Buy | Maintains | |
| 2022-03-18 | Piper Sandler | Overweight | Maintains | |
| 2022-03-14 | Keybanc | Overweight | Sector Weight | Downgrade |
| 2022-03-11 | Needham | Buy | Maintains | |
| 2022-03-11 | Lake Street | Buy | Maintains | |
| 2022-01-07 | Stephens & Co. | Overweight | Initiate | |
| 2021-12-16 | Needham | Buy | Maintains | |
| 2021-11-10 | Needham | Buy | Maintains | |
| 2020-12-16 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2020-11-30 | BTIG | Buy | Initiate | |
| 2020-11-13 | Needham | Buy | Maintains | |
| 2020-11-10 | KeyBanc | Overweight | Initiate | |
| 2020-07-30 | Benchmark | Speculative Buy | Maintains | |
| 2020-07-01 | Needham | Buy | Maintains | |
| 2020-06-30 | Chardan Capital | Buy | Neutral | Downgrade |
| 2020-06-02 | Needham | Buy | Initiate | |
| 2019-02-13 | PiperJaffray | Overweight | Initiate | |
| 2017-02-23 | Chardan Capital | Buy | Initiate | |
| 2016-05-13 | Benchmark | Speculative Buy | Initiate | |
| 2016-03-24 | Lake Street | Buy | Initiate | |
| 2016-03-15 | Janney Capital | Buy | Initiate | |
| 2023-04-04 | Needham | Buy | Maintains | |
| 2023-08-24 | Benchmark | Speculative Buy | Speculative Buy | Maintains |
| 2023-08-15 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-08-10 | Needham | Buy | Buy | Maintains |
| 2023-11-09 | Needham | Buy | Buy | Maintains |
| 2023-11-13 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-04-17 | Stephens & Co. | Equal-Weight | Equal-Weight | Reiterate |
| 2024-04-24 | Needham | Buy | Buy | Maintains |
| 2024-05-16 | Needham | Buy | Buy | Reiterate |
| 2024-04-15 | Benchmark | Speculative Buy | Speculative Buy | Reiterate |
| 2024-08-09 | Needham | Buy | Buy | Reiterate |
| 2024-11-13 | Needham | Buy | Buy | Reiterate |
| 2024-10-15 | Needham | Buy | Buy | Reiterate |
| 2025-04-08 | Needham | Buy | Buy | Reiterate |
| 2025-03-25 | Stephens & Co. | Equal-Weight | Equal-Weight | Reiterate |
| 2025-03-25 | Needham | Buy | Buy | Reiterate |
| 2025-03-28 | Lake Street | Buy | Initiate | |
| 2025-03-26 | Stephens & Co. | Equal-Weight | Equal-Weight | Reiterate |
| 2025-05-13 | Needham | Buy | Buy | Reiterate |
| 2025-05-21 | Lake Street | Buy | Buy | Maintains |
